Skip to content

Attenuation of the Hemodynamic Response to Double-lumen Endotracheal Intubation With Nebulized Lidocaine

Attenuation of the Hemodynamic Response to Double-lumen Endotracheal Intubation With Nebulized Lidocaine: a Randomized, Double-blind, Controlled Trial

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05850702
Enrollment
92
Registered
2023-05-09
Start date
2023-06-15
Completion date
2025-09-09
Last updated
2023-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Neoplasms

Keywords

Double-lumen Endotracheal Intubation

Brief summary

The goal of this clinical trial is to test the effect of nebulized lidocaine on the hemodynamic response in the participant undergoing double-lumen endotracheal intubation. The main question it aims to answer is to evaluate the changes in mean arterial pressure after intubation. Participants will inhale 5ml of 2% lidocaine by nebulization15min before intubation. Researchers will compare saline group to see if saline effects

Interventions

DRUGLidocaine

inhale 5ml of 2% lidocaine by nebulization

DRUGSaline

inhale 5ml of saline by nebulization

Sponsors

RenJi Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. aged 18-65 years, American Society of Anesthesiologists class I-II 2. participants undergoing double-lumen endotracheal intubation under general anesthesia 3. signed informed consent and volunteered to participate in the experiment

Exclusion criteria

1. Poor control of hypertension 2. preoperative arrhythmia 3. severe coronary artery or heart valve disease 4. sequelae of cerebrovascular accident 5. severe lung, liver, kidney and immune system diseases 6. Suspected difficult airway 7. confirmed or suspected allergy to this trial drug 8. As judged by the investigator to be ineligible for the study, such as communication impairment (language or intelligence)

Design outcomes

Primary

MeasureTime frame
mean arterial pressure after intubationImmediately after intubation

Contacts

Primary ContactHao Zhu
zhuhaossmu@163.com008602168383702

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026